BRAF and metastatic melanoma: For example, in this Baylor panel BRAF mutations are targeted, where treatment with vemurafenib and dabrafenib has demonstrated BRAF Val600-specific metastatic melanoma antitumor activity (Jang and Atkins, 2013).